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Summary
Background.— Screening for and management of dyslipidaemia are crucial in primary and sec-
ondary prevention of cardiovascular disease. The impact on general practitioners (GP) of the
2005 French guidelines for hypercholesterolaemia has not been evaluated.
Aims.— To compare GP’s estimation of cardiovascular risk with that from a theoretical cal-
culation; to analyse the consequences of cardiovascular-risk estimation on the threshold of
therapeutic intervention and the target low-density lipoprotein cholesterol (LDL-C) concentra-
tion; and to analyse patients’ awareness of their hypercholesterolaemia.
Methods.— The RESPECT study was a transverse, multicentre, observational survey conducted
between March 2006 and February 2007 by 1797 GP in France. Inclusion criteria were adults
with primary hypercholesterolaemia who had not taken lipid-lowering drugs within the previous
6months.
Results.— Of the 5627 patients included (60.9% men; mean age± standard deviation
58.2± 11.0 years; body mass index 27.2± 4.1 kg/m2; mean total cholesterol 2.68± 0.37 g/L;
LDL-C 1.79± 0.35 g/L), 1963 (36.2%) had at least three cardiovascular risk factors. GP identiﬁed
a high cardiovascular risk level in 40.8%, moderate risk in 45.8% and low risk in 13.4% of
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patients. These compared with calculated rates of 48, 23 and 29%, respectively ( concordance
59.4%). For most patients (98.2%), GP deﬁned the therapeutic target based on LDL-C concen-
tration. The target LDL-C was signiﬁcantly different when cardiovascular risk was estimated
by GP versus that calculated theoretically. The higher the estimated risk level, the greater
the rate of introduction of lipid-lowering drugs and the shorter the time to the next GP visit.
Most patients considered themselves to be well or rather well informed about their cholesterol
concentration (91.3%), the causes (64.3%) and consequences of cholesterol-induced diseases
(83.7%), and the difference between ‘good’ and ‘bad’ cholesterol (57%). Most (81.5%) patients
were aware of the beneﬁts of lipid-lowering drugs on cardiovascular disease prevention;
95.8% considered adequate diet and compliance with pharmacological treatment to be very
important.
Conclusion.— Recent French guidelines for hypercholesterolaemia are used widely by GP in
practice. They enable correct assessment of overall cardiovascular risk level, have an impact
on the therapeutic threshold of intervention by physicians and improve patients’ awareness of
the relevance of cholesterol concentration.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé Le dépistage et la prise en charge des dyslipidémies sont des éléments majeurs
de la prévention primaire et secondaire cardiovasculaire (CV). L’impact des recommanda-
tions franc¸aises de 2005 pour la prise en charge des hypercholestérolémies par les médecins
généralistes (MG) n’a pas été évalué.
Objectif.— Comparer l’estimation du niveau de risque CV par les MG à celui calculé par
une méthode mathématique ; analyser les conséquences de cette estimation sur les mesures
thérapeutiques et le niveau de LDL-cholestérol cible ; analyser les connaissances des patients
sur leur hypercholestérolémie.
Méthodes.— L’étude RESPECT est une étude multicentrique, transversale, observationnelle,
menée de mars 2006 à février 2007 auprès de 1797MG. Les critères d’inclusion principaux
étaient des patients adultes ayant une hypercholestérolémie primaire et n’ayant pas rec¸u de
traitement hypolipémiant durant les six mois précédent l’étude.
Résultats.— Cinq mille six cent vingt-sept patients (77 % d’hommes, âge moyen : 58,2± 11 ans ;
IMC : 27,2± 4,1 kg/m2) ont été inclus. Le cholestérol total était à 2,68± 0,37 g/L, le cholestérol
LDL à 1,9± 0,35 g/L et 1963 (36,2 %) patients avaient au moins trois facteurs de risque CV.
Les MG ont identiﬁé un haut niveau de risque CV chez 40,8 %, un risque modéré chez 45,8 %
et un faible risque chez 13,4 % patients. Les valeurs respectives en utilisant la méthode
de calcul théorique était de 48, 23 et 29 % (concordance kappa, 59,4 %). Pour la majorité
des patients (98,2 %), les MG ont déﬁni une cible thérapeutique basée sur le niveau de
cholestérol LDL. La cible de cholestérol LDL était signiﬁcativement différente quand le niveau
de risque CV était estimé par le MG que lorsqu’il était calculé de manière théorique. Il y avait
une corrélation étroite entre le niveau estimé de risque CV et la prescription d’un traite-
ment hypolipémiant, ainsi que le temps séparant la première consultation de la seconde.
La plupart des patients se considérait comme bien ou assez bien informé sur leur niveau de
cholestérol (91,3 %), les causes (63,4 %) et les conséquences des maladies induites par une hyper-
cholestérolémie (83,7 %) et la différence entre le « bon » et « mauvais » cholestérol (57,2 %).
Les patients étaient informés des bénéﬁces attendus d’un traitement hypolipémiant dans la
prévention des maladies CV (81,5 %). Ils considéraient le plus souvent qu’une diététique adap-
tée et une bonne compliance au traitement pharmacologique ont une importance majeure
(95,8 %).
Conclusion.— Les récentes recommandations franc¸aises de la prise en charge des hyper-
cholestérolémies sont largement appliquées par les MG dans leur pratique quotidienne. Ces
recommandations permettent d’avoir une estimation correcte du niveau de risque CV global.
Elles ont un impact sur le niveau d’intervention thérapeutique utilisée par les praticiens
et améliorent les connaissances sur les pathologies liées aux hypercholestérolémies par les
patients.
© 2008 Elsevier Masson SAS. All rights reserved.
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Abbreviations
AFSSAPS French Health Products Safety Agency
ANAES National Agency of Health Accreditation and Eval-
uation
CHD Coronary heart disease
GP General practitioner
LDL-C Low-density lipoprotein cholesterol
Background
Dyslipidaemia is a major cardiovascular risk factor for the
development of CHD, cerebrovascular disease and periph-
eral arterial disease. Elevated cholesterol concentrations
have been estimated to induce 56% of CHD and 18% of
cerebrovascular disease events [1]. Large clinical trials
have shown that reduction of cholesterol concentration
is associated with a signiﬁcant decrease in cardiovascu-
lar morbidity and mortality [2—5]. Lowering LDL-C slows
atherosclerotic plaque development and reduces the risk of
CHD [6]. It is critically important that patients with lipid
disorders are identiﬁed and treated appropriately to reduce
morbidity and mortality associated with hypercholestero-
laemia.
Several national and international guidelines have been
established to determine the levels of risk associated with
the presence of cardiovascular risk factors and the actions
necessary to reduce the global burden of atherosclerosis. A
patient’s lipid status often presents a subclinical and asymp-
tomatic aspect of their cardiovascular risk level, such as
elevated LDL-C, a well-known major modiﬁable risk fac-
tor. Accurate measurement of LDL-C is now considered the
best marker for determining the threshold of therapeu-
tic intervention and assessing the efﬁcacy of lipid-lowering
drugs.
In France, hypercholesterolaemia is present in 20—30%
of adult patients and has been identiﬁed as a major public
health issue [7]. In 2000, the ANAES edited its recommen-
dations on screening and biological diagnosis procedures
for dyslipidaemia in primary prevention [8]. A few months
later, the AFSSAPS edited their recommendations for the
management of dyslipidemia [9]. In 2005, the AFFSAPS rec-
ommendations were revised to help physicians, particularly
GP, determine the therapeutic threshold and target LDL-
C concentration [9]. These current guidelines simpliﬁed
the rules of screening through a simple laboratory assess-
ment of lipids in all adults and redeﬁned the methods of
cardiovascular-risk assessment.
The aim of the RESPECT (Application of the recent French
guidelines for the management of dyslipidemia in general
practice) study was to analyse the extent of implementation
by French GP of the updated AFSSAPS recommendations for
the assessment and treatment of dyslipidaemia. The ﬁrst
goal was to compare GP’s estimate of cardiovascular risk
with that from a theoretical calculation. The second goal
was to analyse the consequences of such cardiovascular-risk
estimation on the threshold of therapeutic intervention and
target LDL-C concentration. The third goal was to analyse
patients’ awareness of their hypercholesterolaemia and the
relevance of targeted therapy.
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ethods
he RESPECT study was a transverse, multicentre, observa-
ional survey conducted from March 2006 to February 2007
y 1797GP, each of whom included the ﬁrst four patients
ho met the inclusion criteria. Inclusion criteria were adults
≥ 18 years) with primary hypercholesterolaemia, a fasting
aboratory assessment taken within the previous 3months,
ho had not received any lipid-lowering therapy in the pre-
ious 6months and had visited their GP for any reason. This
urvey was strictly observational and did not require changes
n GP’s usual management decisions.
ata collection
hysicians completed a questionnaire for each patient that
ollected data on clinical and laboratory information, car-
iovascular risk factors and medical history. Based on
linical and laboratory investigations, GP estimated each
atient’s cardiovascular risk level as being high, moder-
te or low, and then deﬁned a therapeutic target for
he LDL-C concentration. They decided whether a non-
harmacological approach and/or a medication for the
yperlipidaemia was useful.
The theoretical cardiovascular-risk level was determined
ccording to the ANAES recommendations [10]: high-risk
atients were deﬁned as those with at least one personal his-
ory of cardiovascular disease (that is, CHD, cerebrovascular
isease or peripheral arterial disease) or high-risk diabetes
r a greater than 20% risk of a coronary event occurring in
he next 10 years; moderate-risk patients were deﬁned as
he presence of two or more cardiovascular risk factors; all
thers were identiﬁed as low-risk patients. A family history
f premature CHD was deﬁned as a myocardial infarction
r sudden death in a ﬁrst-degree relative before the age of
5 years in men or 65 years in women.
Each patient completed a questionnaire that collected
ata on their sociodemographics and extent of knowl-
dge about cholesterol-associated cardiovascular disorders,
harmacological and non-pharmacological treatment of
ypercholesterolaemia and awareness of the importance of
herapeutic compliance.
tatistical methods
ased on an expected 7% of patients with high cardiovascu-
ar risk [11], the number of patients needed in this group
as estimated to be 554 to detect 10% of such individu-
ls having a different therapeutic threshold compared with
rench guidelines. The total number of patients required to
erform the study was estimated at 7914. Even though only
069 patients were recruited into the study, the statistical
ower (> 90%) of the sample size means that the ﬁnal number
f patients was satisfactory.
Descriptive statistics used for quantitative parameters
ere mean and standard deviation, median and range, and
issing values. Those used for qualitative parameters were
requency and percentage. Concordance between the GP’s
stimate of cardiovascular risk and the theoretical calcu-
ation based on the ANAES method was evaluated using
7 P. Cacoub et al.
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Table 1 Patients’ main characteristics (n = 5627).
Characteristic n (%) or
mean (S.D.)
na
Age, years 58.2± 11.0 5627
Men, n (%) 3391 (60.9) 5568
Men≥ 50 years, n (%) 2596 (46.6) 5568
Women≥ 60 years, n (%) 1195 (21.5)
Weight, kg 78.0± 13.9 5602
Height, cm 169.0± 8.2 5579
Body mass index, kg/m2 27.2± 4.1 5568
Systolic blood pressure, mmHg 137.1± 13.0 5513
Diastolic blood pressure, mmHg 80.3± 9.0 5509
Total cholesterol, g/L 2.68± 0.37 5570
LDL-C b, g/L 1.79± 0.35 5627
HDL-C, g/L 0.54± 0.17 5627
Triglycerides, g/L 1.63± 0.85 5504
Glycaemia, g/L 1.09± 0.30 4287
Patients with diabetes, n (%) 1089 (19.5) 5591
Glycosylated haemoglobin, n (%) 6.92 (1.29) 1088
Creatininemia, M/L 85.5± 18.1 4187
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density
lipoprotein cholesterol; S.D.: standard deviation.
a Number of patients with available data.
b
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59.4% (w = 0.471). High and moderate risk levels were well
estimated, with 69.0 and 68.9% concordance rates, respec-
tively (Table 2). Conversely, patients with a low calculated
risk level were correctly estimated in only 550 out of 154418
eighted kappa (w). To interpret the kappa ratings, the
enchmarks suggested by Landis and Koch were used [12]
less than 0.8 representing almost perfect concordance;
.6—0.8 good concordance; 0.4—0.6 moderate concordance;
.2—0.4 fair concordance; 0—0.2 slight concordance; less
han 0 poor concordance). All tests were bilateral with an
-risk equal to 0.05. Statistical analysis was performed using
AS® software, version 8.2 (SAS Institute Inc, Cary, NC, USA).
esults
total of 1797GP from all metropolitan areas in France
articipated in the RESPECT study. The GP’s mean age
as 50.5± 7.0 years (range 32—84) and 90% were men. The
ajority (63%) practised in towns with less than 20,000
nhabitants (36% in a town with less than 5000 inhabitants),
8% with 20,000 to 100,000, 6% with 100,000 to 200,000, 9%
ith 200,000 to two million, and 4% in the Paris area (less
han two million).
atient proﬁle
f the 7069 patients recruited, 1442 (20.4%) were excluded
rom the analysis due to major protocol deviations, includ-
ng missing date of lipid assessment (n = 988) or missing
igh-density lipoprotein cholesterol (HDL-C; n = 560) and/or
DL-C (n = 261) concentration. The main demographic and
linical baseline characteristics were not statistically dif-
erent for excluded and included patients (data not shown).
The RESPECT study population comprised 5627 adults
ith hypercholesterolaemia. Their main clinical and labo-
atory characteristics are summarized in Table 1. Age was a
ardiovascular risk factor for 77% of men (2596 out of 3391
ere greater than 50 years) and for 55% of women (1195 out
f 2177 were greater than 60 years). Laboratory assessment
ad been carried out within the past 28± 33 days (median
4 days), and included total cholesterol, LDL-C (calculated
sing the Friedewald formula when direct measurement was
ot available), HDL-C and triglyceride concentrations in 99%
f cases and fasting glycaemia in 89%.
stimate of cardiovascular risk
he distribution of the main cardiovascular risk factors is
hown in Fig. 1. In this population of patients with primary
ypercholesterolaemia, the most frequent cardiovascular
isk factors were older age (68%), hypertension (55%, treated
n 95%), current or recent smoking (40%), family history of
remature CHD (36.5%), diabetes (19.5%, type 2 in 89%) and
ersonal cardiovascular history (19%). HDL-C concentration
< 0.40 g/L) was a cardiovascular risk factor for 15.2% of
atients, while it was protective (≥ 0.60 g/L) for 31%. The
istribution of cardiovascular risk factors showed that 1963
36.2%) patients had at least three cardiovascular risk fac-
ors, 1547 (28.5%) had two cardiovascular risk factors and
913 (35.3%) had one or no cardiovascular risk factors (1215
nd 698, respectively). The ‘‘no cardiovascular risk factor’’
eature was possible when HDL-C concentration was protec-
ive (that is, ≥ 0.60 g/L), enabling one cardiovascular risk FCalculated using the Friedewald formula when direct measure-
ment was not available.
actor to be subtracted from the total number of risk fac-
ors.
Kappa concordance between cardiovascular-risk level
stimated by the GP and that calculated theoretically wasigure 1. Distribution of the main cardiovascular risk factors.
The RESPECT study 719
Table 2 Concordance between GP estimate of cardiovascular risk and theoretical risk.
Theoretical risk Total GP estimate of risk
Low Moderate n (%) High
Low 1544 55 (35.6) 853 (55.2) 141 (9.1)
Moderate 1248 96 (7.7) 860 (68.9) 292 (23.4)
High 2603 64 (2.5) 744 (28.6) 179 (69.0)
Overall population 5395 71 (13.2) 245 (45.5) 222 (41.3)
ANAES method.
GP started lipid-lowering medications in 5158 out of 5627
(91.7%) patients. Use of these therapies rose with increasing
estimated cardiovascular risk, being prescribed in 98.5% of
Table 3 Therapeutic target for LDL-C concentration
according to level of cardiovascular risk.
GP estimate of risk
Low n (%) Moderate High
LDL-C (g/L) n = 684 n = 2457 n = 2232
< 2.20 88 (12.9) 27 (1.1) 6 (0.3)
< 1.90 190 (27.8) 168 (6.8) 18 (0.8)
< 1.60 270 (39.5) 873 (35.5) 81 (3.6)
< 1.30 127 (18.6) 1206 (49.1) 557 (25.0)
< 1.00 9 (1.3) 183 (7.4) 1570 (70.3)
Theoretical cardiovascular risk
Lowa Moderateb n (%) High
LDL-C (g/L) n = 1493 n = 1240 n = 2592
< 2.20 101 (6.8) 9 (0.7) 9 (0.3)
< 1.90 296 (19.8) 37 (3.0) 41 (1.6)
< 1.60 525 (35.2) 415 (33.5) 266 (10.3)
< 1.30 478 (32.0) 634 (51.1) 758 (29.2)
< 1.00 93 (6.2) 145 (11.7) 1518 (58.6)
LDL-C: low-density lipoprotein cholesterol.
a Zero or one cardiovascular factor.
b Two or greater or equal to three cardiovascular risk factors.
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tigh-risk, 93.5% of moderate-risk patients and 78.2% of low-
isk patients. Statins were prescribed in 5045 out of 5158
97.8%) patients; the rate increased to 98.7% in patients with
high estimated cardiovascular risk.
GP planned a control visit within 3months of the initial
isit in 74% of patients. The higher the estimated cardiovas-
ular risk, the shorter the time to the next visit: 1—3months
or 74.3% of patients estimated at low risk, 86.2% at mod-
rate risk and 92.5% at high risk. Of the high-risk patients,
7.3% were scheduled to have an even earlier control visit,
ithin 1month. Overall, 88.7% of all patients, and 90.8% of
hose who had been prescribed cholesterol-lowering treat-
ent, had previously received lifestyle recommendations
ithin the past 9± 13months. These recommendations were
iven by either the GP (89.6%) or a dietician (1.3%) or both
5.6%). A laboratory control test was planned over the next
—3months in 93.7% of patients (that is, 90.5% of patients
t high risk versus 75.6% of those at low risk).
atient’s perception of
ypercholesterolaemia
ata from the patient self-questionnaire showed that the
atient’s LDL-C concentration was frequently reported to
hem by their GP (89.1%). Although only 53.6% of patients
ould remember this ﬁgure, the majority (89.1%) had mem-
rized the target LDL-C concentration.
A high cholesterol concentration was considered to be
cardiovascular risk factor by 65.2% of patients, as a
isease by 26.2% and as an insigniﬁcant laboratory abnor-
ality by 9.4%. Most patients considered themselves to
e either well or rather well informed about their choles-
erol concentration (91.3%), about the causes (64.3%) and
he consequences of cholesterol-induced diseases (83.7%),
nd the difference between ‘good’ and ‘bad’ cholesterol
57.2%).
Over four-ﬁfths (81.5%) of patients were aware of the
eneﬁts of lipid-lowering treatment on CHD prevention,
nd most (95.8%) considered adequate diet and compliance
ith pharmacological treatment to be very important. Some
atients thought that lowering cholesterol would lead to
eight loss (12.9%), enable eating without restriction (9.7%)GP: general practitioner.
(35.6%) patients. Investigators frequently overestimated the
cardiovascular risk level in this group, as they considered
55.2% of patients to have a moderate cardiovascular risk
level, or even to be at high risk in 9.1% of patients.
Target LDL-C and therapeutic management
For most (98.2%) patients, GP deﬁned the therapeutic tar-
get based on the LDL-C concentration, that is, less than
1.60 g/L for 22.9% patients, less than 1.30 g/L for 35.2%
and less than 1.00 g/L for 32.6% (Table 3). The target LDL-
C concentration was different when the cardiovascular risk
was estimated by the GP and then calculated. For example,
95.3% of GP-estimated high-risk patients had a LDL-C target
less than 1.30 g/L versus 87.8% when calculated using ther provide no beneﬁts (0.3%). In fact, 80.9% had previously
een given dietary advice, although 59.5% considered it
ifﬁcult to adhere to dietary rules. The self-questionnaire
ighlighted poor knowledge concerning the duration of drug
herapy, although 95.8% of patients were aware of the
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mportance of complying with the therapy prescribed by
heir GP.
iscussion
he aim of the RESPECT study was to describe the current
are of hypercholesterolaemic patients by French primary
are physicians. Estimating a patient’s risk of cardiovas-
ular events is of major importance, particularly in the
eld of hypercholesterolaemia where most algorithm guide-
ines are based on individualized risk. In the present study,
oderate and high levels of cardiovascular risk were esti-
ated accurately, but GP overestimated risk in those at
ow risk. While this approach might lead to better follow-up
nd closer management, it could also result in unnecessary
ealthcare expenditure. The level of cardiovascular risk also
nﬂuences the threshold for therapeutic intervention. The
ata from the present study suggest that GP were more likely
o treat hypercholesterolaemia aggressively when they per-
eived that patients were at higher risk. In France, many
tudies have reported the undertreatment of high-risk and
he overtreatment of low-risk dyslipidaemic patients [7,13].
he present survey conﬁrms the widespread use of statins
or initiating cholesterol-lowering pharmacological therapy,
n line with AFSSAPS guidelines, although they were started
ater than recommended (at a mean of 9months after giving
ifestyle advice versus within 3months as recommended in
uidelines).
The target LDL-C compared with the cardiovascular
isk level estimated by GP, and showed that patients at
igh cardiovascular risk were better screened, given a
ore appropriate target LDL-C concentration and a closer
ollow-up schedule than low-risk patients. Compared with
previous survey assessing adherence in primary care to
he NCEP ATP II guidelines [14] or the recent PRAGMA study
15], these results showed an improvement in determining
atients’ overall risk. This ﬁnding highlights the need for
imple scales of cardiovascular risk factors and therapeu-
ic decision-making in order to facilitate determination of a
atient’s therapeutic threshold and target LDL-C.
The higher the estimated cardiovascular risk, the greater
as the rate of prescription of lipid-lowering therapy, most
f which were statins. Large clinical studies [16—18] have
emonstrated the clinical efﬁcacy of a dramatic reduction
n LDL-C in patients at moderate or high risk. Recently, the
tudy of Practice versus Objectives of Treatment (SPOT)
tudy showed that cardiovascular prevention with lipid-
owering drugs, used according to the AFSSAPS guidelines,
as improved in France. In primary prevention and in low-
isk patients, the recommended objectives were achieved
n 95% of cases; conversely, patients at high risk were less
ikely to achieve them [7]. In the EUROASPIRE study, which
oncerned secondary prevention of CAD [19], major ben-
ﬁts were obtained with the widespread use of practice
uidelines. Some difﬁculties were encountered, however,
n maintaining sufﬁcient compliance with these recommen-
ations by physicians and patients [20]. A French study
Paris Cardiovascular Risk Factor Prevention Trial) high-
ighted the threat of failure to implement guidelines [21],
ainly in the moderate-risk population. Conversely, the
ntervention had a favourable effect in high-risk patients.P. Cacoub et al.
umerous guidelines (AFSSAPS, NCEP) have been published
9,10,22], identifying elevated LDL-C as the primary target
f cholesterol-lowering therapy. North American, European
nd French guidelines have highlighted the need to integrate
creening and management of the moderate-risk population
n daily general practice [6,8,9,22].
In the present study, patients were aware of the ben-
ﬁts of lipid-lowering treatment on CHD prevention, with
ost believing that adequate diet and compliance with
harmacological treatment was of great importance. These
ata suggest that awareness has improved recently in both
hysicians and patients, when compared with the results
f an earlier study conducted in France and Northern Ire-
and [23]. This awareness needs to be increase further,
hrough reinforcement of physicians’ skills and availability
f information on cholesterol dosage and hypercholestero-
aemia. Patient compliance is essential in order to reach
nd maintain the recommended therapeutic targets for their
articular level of cardiovascular risk [24].
tudy limitations
his was a transverse observational study, which, by its
ature, did not take into account patient follow-up; man-
gement and control of cardiovascular risk factors is a long
rocess from which cardiovascular beneﬁt can be assessed
nly after a long interval. Further observational trials con-
ucted over a longer period may conﬁrm the positive trend
owards this major public health objective.
onclusions
ecent French guidelines for the management of hyperc-
olesterolaemia are used widely by GP in daily practice.
hese guidelines have an impact on the therapeutic thresh-
ld of intervention used by GP, and increase patients’
wareness of the importance of cholesterol concentrations.
creening and management of adult patients with hyperc-
olesterolaemia appears to be widely in line with revised
FSSAPS guidelines. Ongoing educational efforts targeting
oth physicians and patients are warranted, particularly
or high-risk patients who could be treated more aggres-
ively, whereas low-risk patients are often misclassiﬁed by
isk overestimation.
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